Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 211

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Colchicine in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Open access
· 2021 · The Lancet Respiratory Medicine

Abstract

SUMMARY Background Colchicine has been proposed as a treatment for COVID-19 on the basis of its anti-inflammatory actions. Methods In this randomised, controlled, open-label trial, several possible treatments were compared with usual care in patients hospitalised with COVID-19. Eligible and consenting adults were randomly allocated in a 1:1 ratio to either usual standard of care alone or usual standard of care plus colchicine twice daily for 10 days or until discharge (or one of the other treatment arms) using web-based simple (unstratified) randomisation with allocation concealment. The primary outcome was 28-day mortality. The trial is registered with ISRCTN (50189673) and clinicaltrials.gov ( NCT04381936 ). Findings Between 27 November 2020 and 4 March 2021, 5610 patients were randomly allocated to receive colchicine and 5730 patients to receive usual care alone. Overall, 1173 (21%) patients allocated to colchicine and 1190 (21%) patients allocated to usual care died within 28 days (rate ratio 1.01; 95% confidence interval [CI] 0.93-1.10; p=0.77). Consistent results were seen in all pre-specified subgroups of patients. There was no significant difference in duration of hospitalisation (median 10 days vs. 10 days) or the proportion of patients discharged from hospital alive within 28 days (70% vs. 70%; rate ratio 0.98; 95% CI 0.94-1.03; p=0.44). Among those not on invasive mechanical ventilation at baseline, there was no significant difference in the proportion meeting the composite endpoint of invasive mechanical ventilation or death (25% vs. 25%; risk ratio 1.02; 95% CI 0.96-1.09; p=0.47). Interpretation In adults hospitalised with COVID-19, colchicine was not associated with reductions in 28-day mortality, duration of hospital stay, or risk of progressing to invasive mechanical ventilation or death. Funding UK Research and Innovation (Medical Research Council) and National Institute of Health Research (Grant ref: MC_PC_19056). Wellcome Trust (Grant Ref: 222406/Z/20/Z) through the COVID-19 Therapeutics Accelerator.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s2213-2600(21)00435-5

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Research works printed but not linked: 20

  1. Huang, 2020, Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China, Lancet, 395, 497, 10.1016/S0140-6736(20)30183-5 · DOI · Paper page
  2. Wang, 2021, Inflammation-associated factors for predicting in-hospital mortality in patients with COVID-19, J Med Virol, 93, 2908, 10.1002/jmv.26771 · DOI
  3. Thwaites, 2021, Inflammatory profiles across the spectrum of disease reveal a distinct role for GM-CSF in severe COVID-19, Sci Immunol, 6, eabg9873, 10.1126/sciimmunol.abg9873 · DOI · Paper page
  4. McElvaney, 2020, Characterization of the inflammatory response to severe COVID-19 illness, Am J Respir Crit Care Med, 202, 812, 10.1164/rccm.202005-1583OC · DOI · Paper page
  5. Dorward, 2021, Tissue-specific immunopathology in fatal COVID-19, Am J Respir Crit Care Med, 203, 192, 10.1164/rccm.202008-3265OC · DOI · Paper page
  6. 2021, Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial, Lancet, 397, 1637, 10.1016/S0140-6736(21)00676-0 · DOI · Paper page
  7. Kalil, 2020, Baricitinib plus remdesivir for hospitalized adults with Covid-19, N Engl J Med, 384, 795, 10.1056/NEJMoa2031994 · DOI · Paper page
  8. Broz, 2016, Inflammasomes: mechanism of assembly, regulation and signalling, Nat Rev Immunol, 16, 407, 10.1038/nri.2016.58 · DOI · Paper page
  9. Dalbeth, 2014, Mechanism of action of colchicine in the treatment of gout, Clin Ther, 36, 1465, 10.1016/j.clinthera.2014.07.017 · DOI · Paper page
  10. Fiolet, 2021, Efficacy and safety of low-dose colchicine in patients with coronary disease: a systematic review and meta-analysis of randomized trials, Eur Heart J, 42, 2765, 10.1093/eurheartj/ehab115 · DOI · Paper page
  11. Martinez, 2018, The NLRP3 inflammasome and the emerging role of colchicine to inhibit atherosclerosis-associated inflammation, Atherosclerosis, 269, 262, 10.1016/j.atherosclerosis.2017.12.027 · DOI · Paper page
  12. Salehzadeh, 2020, The impact of colchicine on the COVID-19 patients; a clinical trial study, Research Square
  13. Lopes, 2021, Beneficial effects of colchicine for moderate to severe COVID-19: a randomised, double-blinded, placebo-controlled clinical trial, RMD Open, 7, e001455, 10.1136/rmdopen-2020-001455 · DOI · Paper page
  14. Deftereos, 2020, Effect of colchicine vs standard care on cardiac and inflammatory biomarkers and clinical outcomes in patients hospitalized with coronavirus disease 2019: the GRECCO-19 randomized clinical trial, JAMA Netw Open, 3, e2013136, 10.1001/jamanetworkopen.2020.13136 · DOI · Paper page
  15. Horby, 2020, Effect of hydroxychloroquine in hospitalized patients with Covid-19, N Engl J Med, 383, 2030, 10.1056/NEJMoa2022926 · DOI · Paper page
  16. 2020, Lopinavir-ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial, Lancet, 396, 1345, 10.1016/S0140-6736(20)32013-4 · DOI · Paper page
  17. 2021, Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial, Lancet, 397, 605, 10.1016/S0140-6736(21)00149-5 · DOI · Paper page
  18. 2021, Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial, Lancet, 397, 2049, 10.1016/S0140-6736(21)00897-7 · DOI · Paper page
  19. Deftereos, 2020, The Greek study in the effects of colchicine in COvid-19 complications prevention (GRECCO-19 study): rationale and study design, Hellenic J Cardiol, 61, 42, 10.1016/j.hjc.2020.03.002 · DOI
  20. Tardif, 2021, Colchicine for community-treated patients with COVID-19 (COLCORONA): a phase 3, randomised, double-blinded, adaptive, placebo-controlled, multicentre trial, Lancet Respir Med, 9, 924, 10.1016/S2213-2600(21)00222-8 · DOI · Paper page

Cited by

See all 211

Metadata

Venue
The Lancet Respiratory Medicine
Publisher
Elsevier BV
Published
2021-12
Volume
9
Issue
12
Pages
1419-1426
ISSN
2213-2600 (ISSN-L)
OpenAlex
W4226264587
Cited by
211
References
8
FWCI
13.92
Type
journal article
Language
en
Open access
hybrid
Licence
Funders
  • Department of Health and Social Care (COVID-19)
  • Roche
  • Public Health England
  • Bill and Melinda Gates Foundation
  • UK Research and Innovation
  • Medical Research Council (MC_PC_19056, MC_UU_0002/14)
  • Swansea University
  • Wellcome Trust (222406/Z/20/Z)
  • National Institute for Health Research
  • NIHR Oxford Biomedical Research Centre

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Colchicine in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. https://app.cochat.ai/papers/10.1016/s2213-2600(21)00435-5
The paper
Colchicine in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. (2021). The Lancet Respiratory Medicine. https://doi.org/10.1016/s2213-2600(21)00435-5

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.